Seroatlas · Human Serome Atlas

MYOM2

Myomesin-2

Also known as: MYOM2_HUMAN

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession: P54296
Gene: MYOM2
Ensembl: ENSG00000036448
Chromosome: 8
Canonical length: 1465 aa
Protein class: Predicted intracellular proteins
Subcellular location: Mitochondria

OverviewNCBI Gene

The giant protein titin, together with its associated proteins, interconnects the major structure of sarcomeres, the M bands and Z discs. The C-terminal end of the titin string extends into the M line, where it binds tightly to M-band constituents of apparent molecular masses of 190 kD and 165 kD. The predicted MYOM2 protein contains 1,465 amino acids. Like MYOM1, MYOM2 has a unique N-terminal domain followed by 12 repeat domains with strong homology to either fibronectin type III or immunoglobulin C2 domains. Protein sequence comparisons suggested that the MYOM2 protein and bovine M protein are identical. [provided by RefSeq, Jul 2008]

Canonical amino-acid sequenceUniProt

1465 residues, UniProt reviewed canonical sequence.

>P54296|MYOM2
     1  MSLVTVPFYQ KRHRHFDQSY RNIQTRYLLD EYASKKRAST QASSQKSLSQ RSSSQRASSQ
    61  TSLGGTICRV CAKRVSTQED EEQENRSRYQ SLVAAYGEAK RQRFLSELAH LEEDVHLARS
   121  QARDKLDKYA IQQMMEDKLA WERHTFEERI SRAPEILVRL RSHTVWERMS VKLCFTVQGF
   181  PTPVVQWYKD GSLICQAAEP GKYRIESNYG VHTLEINRAD FDDTATYSAV ATNAHGQVST
   241  NAAVVVRRFR GDEEPFRSVG LPIGLPLSSM IPYTHFDVQF LEKFGVTFRR EGETVTLKCT
   301  MLVTPDLKRV QPRAEWYRDD VLLKESKWTK MFFGEGQASL SFSHLHKDDE GLYTLRIVSR
   361  GGVSDHSAFL FVRDADPLVT GAPGAPMDLQ CHDANRDYVI VTWKPPNTTT ESPVMGYFVD
   421  RCEVGTNNWV QCNDAPVKIC KYPVTGLFEG RSYIFRVRAV NSAGISRPSR VSDAVAALDP
   481  LDLRRLQAVH LEGEKEIAIY QDDLEGDAQV PGPPTGVHAS EISRNYVVLS WEPPTPRGKD
   541  PLMYFIEKSV VGSGSWQRVN AQTAVRSPRY AVFDLMEGKS YVFRVLSANR HGLSEPSEIT
   601  SPIQAQDVTV VPSAPGRVLA SRNTKTSVVV QWDRPKHEED LLGYYVDCCV AGTNLWEPCN
   661  HKPIGYNRFV VHGLTTGEQY IFRVKAVNAV GMSENSQESD VIKVQAALTV PSHPYGITLL
   721  NCDGHSMTLG WKVPKFSGGS PILGYYLDKR EVHHKNWHEV NSSPSKPTIL TVDGLTEGSL
   781  YEFKIAAVNL AGIGEPSDPS EHFKCEAWTM PEPGPAYDLT FCEVRDTSLV MLWKAPVYSG
   841  SSPVSGYFVD FREEDAGEWI TVNQTTTASR YLKVSDLQQG KTYVFRVRAV NANGVGKPSD
   901  TSEPVLVEAR PGTKEISAGV DEQGNIYLGF DCQEMTDASQ FTWCKSYEEI SDDERFKIET
   961  VGDHSKLYLK NPDKEDLGTY SVSVSDTDGV SSSFVLDPEE LERLMALSNE IKNPTIPLKS
  1021  ELAYEIFDKG RVRFWLQAEH LSPDASYRFI INDREVSDSE IHRIKCDKAT GIIEMVMDRF
  1081  SIENEGTYTV QIHDGKAKSQ SSLVLIGDAF KTVLEEAEFQ RKEFLRKQGP HFAEYLHWDV
  1141  TEECEVRLVC KVANTKKETV FKWLKDDVLY ETETLPNLER GICELLIPKL SKKDHGEYKA
  1201  TLKDDRGQDV SILEIAGKVY DDMILAMSRV CGKSASPLKV LCTPEGIRLQ CFMKYFTDEM
  1261  KVNWCHKDAK ISSSEHMRIG GSEEMAWLQI CEPTEKDKGK YTFEIFDGKD NHQRSLDLSG
  1321  QAFDEAFAEF QQFKAAAFAE KNRGRLIGGL PDVVTIMEGK TLNLTCTVFG NPDPEVIWFK
  1381  NDQDIQLSEH FSVKVEQAKY VSMTIKGVTS EDSGKYSINI KNKYGGEKID VTVSVYKHGE
  1441  KIPDMAPPQQ AKPKLIPASA SAAGQ

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against MYOM2 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability: Intracellular
Secreted: No
Transmembrane segments: 0
Mean surface accessibility (rSASA): 0.33
Highest tissue expression: 372 nTPM

Expression across tissuesHPA

Tissue

skeletal muscle: 372 nTPM
heart muscle: 325 nTPM
tongue: 58 nTPM
breast: 5.7 nTPM
cerebral cortex: 4.2 nTPM
prostate: 3.5 nTPM

Single-cell type

cardiomyocytes: 417 nCPM
myonuclei: 115 nCPM
epicardial cells: 46 nCPM
early primary spermatocytes: 39 nCPM
thymic myoid cells: 34 nCPM
astrocytes: 25 nCPM

Immune cell

naive B-cell: 0.2 nTPM
naive CD4 T-cell: 0.1 nTPM
basophil: 0 nTPM
classical monocyte: 0 nTPM
eosinophil: 0 nTPM
gdT-cell: 0 nTPM

Brain region

cerebellum: 4.9 nTPM
cerebral cortex: 4.8 nTPM
white matter: 4.1 nTPM
hippocampal formation: 3.3 nTPM
basal ganglia: 3.2 nTPM
amygdala: 1.9 nTPM

DiseaseUniProt · ClinVar · IEDB · PubMed

Four sources answering four different questions about MYOM2.

Disease | GeneticClinVar

1 pathogenic / likely-pathogenic of 550 ClinVar records.

Conditions with pathogenic or likely-pathogenic variants.

Sudden cardiac death

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance): 1.48
gnomAD pLI: 0
gnomAD missense Z: -5.3
DepMap mean gene effect: 0.05
DepMap dependency class: none

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 3% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

Cellular components

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

InteractionsUniProt · HPA

Protein binding partners of MYOM2 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads MYOM2 as an antibody target. Whether an autoantibody or antibody against MYOM2 could matter depends on whether native MYOM2 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

MYOM2 is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.

Annotation status

The present source text does not explicitly label MYOM2 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Loading the interactive Seroatlas protein explorer...